Metabolism of endosulfan-α by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4

Drug Metabolism and Disposition

Volumn 34, Issue 10, 2006, Pages 1779-1785

  Casabar, Richard C T ^a   Wallace, Andrew D ^a   Hodgson, Ernest ^a   Rose, Randy L ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; ENDOSULFAN; ENDOSULFAN ALPHA; ENDOSULFAN SULFATE; KETOCONAZOLE; METHYLTRANSFERASE; OXYGENASE; RECOMBINANT ENZYME; S MEPHENYTOIN N DEMETHYLASE; TESTOSTERONE 6 BETA HYDROXYLASE; TICLOPIDINE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER METABOLISM; LIVER MICROSOME; METABOLISM; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ENDOSULFAN; ENZYME INHIBITORS; HUMANS; INSECTICIDES; KETOCONAZOLE; KINETICS; MICROSOMES, LIVER; MOLECULAR STRUCTURE; OXIDOREDUCTASES, N-DEMETHYLATING; OXYGENASES; STEROID HYDROXYLASES; SULFATES; TICLOPIDINE;

EID: 33748894308     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.010199     Document Type: Article

References (28)

1. [ATSDR] Agency for Toxic Substances and Disease Registry (2000) Toxicological Profile for Endosulfan. Agency for Toxic Substances and Disease Registry (ATSDR), U.S. Department of Health and Human Services, Washington, D.C.
2. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
3. Bumpus NN, Sridar C, Kent UM, and Hollenberg PF (2005) The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation. Drug Metab Dispos 33:795-802.
4. Casabar R, Wallace A, and Rose R (2005) Endosulfan induces cytochrome P450-3A4 and 2B6 through the steroid and xenobiotic receptor (Poster Abstract # 244), in International Society for the Study of Xenobiotics. Abstracts from 13th ISSX Meeting, October 23-27, 2005, Maui, HI, pp 141. Drug Metab Rev 37:244.
5. Cerrillo I, Granada A, Lopez-Espinosa MJ, Olmos B, Jimenez M, Cano A, Olea N, and Fatima Olea-Serrano M (2005) Endosulfan and its metabolites in fertile women, placenta, cord blood, and human milk. Environ Res 98:233-239.
6. [CFR] Code of Federal Regulations (2006) Appendix B to Part 136 - Definition and procedure for the determination of the method detection limit - Revision 1.11, Electronic Code of Federal Regulations, Title 40, Feb 2006.
7. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, and Waxman DJ (1997) Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 25:985-993.
8. Deema P, Thompson E, and Ware GW (1966) Metabolism, storage, and excretion of C-14-endosulfan in the mouse. J Econ Entomol 59:546-550.
9. Dorough HW, Huhtanen K, Marshall TC, and Bryant HE (1978) Fate of endosulfan in rats and toxicological considerations of apolar metabolites. Pestic Biochem Physiol 8:241-252.
10. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, and Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-1230.
11. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, and de Waziers I (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:295-306.
12. Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349-355.
13. Gupta PK and Gupta RC (1977) Effect of endosulfan pretreatment on organ weights and on pentobarbital hypnosis in rats. Toxicology 7:283-288.
14. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, and Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176-1183.
15. Heyn H, White RB, and Stevens JC (1996) Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 24:948-954.
16. Huang Z, Roy P, and Waxman DJ (2000) Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 59:961-972.
17. Khanna RN, Misra D, Anand M, and Sharma HK (1979) Distribution of endosulfan in cat brain. Bull Environ Contam Toxicol 22:72-79.
18. Ko JW, Desta Z, and Flockhart DA (1998) Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6. Drug Metab Dispos 26:775-778.
19. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, and Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415.
20. Lee HK, Moon JK, Chang CH, Choi H, Park HW, Park BS, Lee HS, Hwang EC, Lee YD, Liu KH, et al. (2006) Stereoselective metabolism of endosulfan by human liver microsomes and human cytochrome P450 isoforms. Drug Metab Dispos 34:1090-1095.
21. Nomeir AA, Ruegg C, Shoemaker M, Favreau LV, Palamanda JR, Silber P, and Lin CC (2001) Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates. Drug Metab Dispos 29:748-753.
22. Richter T, Murdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, and Zanger UM (2004) Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 308:189-197.
23. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping - attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
24. Saiyed H, Dewan A, Bhatnagar V, Shenoy U, Shenoy R, Rajmohan H, Patel K, Kashyap R, Kulkarni P, Rajan B, et al. (2003) Effect of endosulfan on male reproductive development. Environ Health Perspect 111:1958-1962.
25. [USEPA] U.S. Environmental Protection Agency (2002) Reregistration Eligibility Decision (R.E.D) for Endosulfan. U.S. Environmental Protection Agency (USEPA), Washington, D.C.
26. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, and Desta Z (2003) The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287-300.
27. Wilson VS and LeBlanc GA (1998) Endosulfan elevates testosterone biotransformation and clearance in CD-1 mice. Toxicol Appl Pharmacol 148:158-168.
28. Yuan R, Madani S, Wei XX, Reynolds K, and Huang SM (2002) Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311-1319.